The 3:40 PM PT session will center on two primary programs currently moving through the development pipeline. Dr. Kumar is set to discuss the ongoing Phase 1 trial of a CAR-T therapy for recurrent ovarian cancer, a project conducted alongside the Moffitt Cancer Center that has shown promising survival metrics without dose-limiting toxicities. The update also covers the completed Phase 1 trial for a breast cancer vaccine developed with the Cleveland Clinic, which successfully met its primary endpoints.

Beyond data review, the presentation aims to contextualize these findings within the broader immunotherapy landscape. Dr. Kumar noted that the company’s vaccine results mirror positive trends seen in recent melanoma trials, despite employing distinct technological approaches. Following the formal presentation, management will host a breakout session for direct engagement with investors. The summit brings together a select group of public companies to present to the institutional investment community, with interested parties encouraged to coordinate meetings via LD Micro representatives.